Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Recruiting

Phase 1

Phase 2

BDTX-4933Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Sponsor:

Institut de Recherches Internationales Servier

Code:

NCT05786924

Conditions

Non-small Cell Lung Cancer

Histiocytic Neoplasm

Histiocytosis

BRAF Gene Mutation

BRAF V600E

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

S241656

FOLFOX6/FOLFOX7

FOLFIRI

Cetuximab

Panitumumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-07. This information was provided to ClinicalTrials.gov by Institut de Recherches Internationales Servier on 2025-11-03.